FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2025 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Orion Debuts 3 New Styles From Cottelli Lingerie

Orion Wholesale has introduced three new styles from its Cottelli Lingerie line.

CAM4, Lovense Introduce New 'Interactive Control' Features

CAM4 has debuted a new suite of interactive Lovense control features for models.

Blush Debuts 3 New Vibes From 'Sexy Things' Collection

Blush has introduced three new vibrators from its Sexy Things collection.

Holiday Products, Sugar Splash Sign Distro Deal

Holiday Products has signed a distribution deal with wellness brand Sugar Splash.

Le Wand Introduces 'Classique' Vibe Collection

Le Wand has debuted its new Classique vibrator line.

Orion Debuts 'Vibrating Prostate Plug With Moving Rings' From 'Anos' Line

Orion Wholesale has introduced the Vibrating Prostate Plug with Moving Rings from its Anos line.

Fleshlight, Vixen Launch New Product Line

Fleshlight and Vixen Media Group (VMG) have partnered to launch the new Vixen x Fleshlight line.

Orion Debuts 'Masturbator 10' Stroker

Orion Wholesale has introduced the Masturbator 10 stroker from its What You Never Expected (WYNE) line.

Svakom Debuts 'DuoGlow' 5-in-1 Vibe

Svakom has introduced its new DuoGlow five-function vibrator.

Eversense Toys Launches 'Crowdfundr' Campaign

Pleasure brand Eversense Toys has launched a Crowdfundr campaign.

Show More